.The biotech will start charging for the drug in COVID-19 after that, and it might not be just a year or two of revenue flow.
The company will pivot to a commercial plan after the donated supply of 1.5 million doses runs out around June or early July, SVB Leerink analyst Geoffrey Porges wrote in an investor note Monday after talking to Gilead CFO Andrew Dickinson.
Its price? Dickinson quoted the $30,000-per-patient price that one recent cost-effectiveness analysis suggested, and said Gilead will charge a fraction of that, Porges wrote.
The Institute for Clinical and Economic Review recently found remdesivir would be cost-effective at $28,670 if the analysis used as a benchmark the common $100,000 per incremental quality-adjusted life-year gained. But the U.S. drug cost watchdog argued that $50,000/QALY should be applied to remdesivir during a public health emergency. After that calculation, ICER pegged a reasonable price at $4,460...
Full text at GMPnews.Net